Rising patient awareness and improving affordability also contribute to expanding GLP-1 drug uptake
With this in mind, DPP-4 inhibitors represent a good choice for patients with high cardiovascular risk, but they are not a first-line consideration for cardiovascular protection compared to SGLT2 inhibitors or glucagon-like peptide-1 receptor agonists, which showed greater CV benefits [35], [27]
Semaglutides design is commonly discussed in relation to peptide stability, receptor interaction, and albumin-binding strategy
These tablets are meant as options for those who have tried standard weight loss methods without success
How many units of semaglutide is 0.25 mg from a 10mg vial
Report suspected side effects to the MHRA Yellow Card Scheme and attend routine reviews every 36 months to assess HbA1c, weight changes, and treatment tolerability